TY - GEN
T1 - Polymeric nanoparticles as immunomodulatory vaccine adjuvants for atherosclerosis
AU - Ahuja, Sonali
AU - Petersen, Latrisha K.
AU - Moghe, Prabhas V.
AU - Uhrich, Kathryn
N1 - Publisher Copyright:
© 2014 IEEE.
PY - 2014/12/2
Y1 - 2014/12/2
N2 - Atherosclerosis, defined as the buildup of lipid-rich plaques in arterial walls, is triggered by a low-level immune response to oxidized low-density lipoproteins (oxLDL). Current strategies target the hepatic synthesis of LDL and lack the ability to actually treat the cause of the disease, which is the body's response to the oxLDL. In this study, we have identifiied a new class of nanoparticle- (NP) based vaccine adjuvants capable of modulating the body's immune response. The degree of NP internalization and its effect on surface expression of several key markers in immune modulation, CD40, CD86, CD80, HLA-DR and HLA-DQ, were evaluated in primary human dendritic cells (DCs). The results suggest that M12PEG, TL12PEG, TD12PEG, and TMeso12PEG were the most successful NP formulations at modulating a non-specific immune response (adjuvant capacity) in dendritic cells. These studies provide a promising strategy for the design and development of amphiphilic NP adjuvants for potential use as an atherosclerosis vaccine.
AB - Atherosclerosis, defined as the buildup of lipid-rich plaques in arterial walls, is triggered by a low-level immune response to oxidized low-density lipoproteins (oxLDL). Current strategies target the hepatic synthesis of LDL and lack the ability to actually treat the cause of the disease, which is the body's response to the oxLDL. In this study, we have identifiied a new class of nanoparticle- (NP) based vaccine adjuvants capable of modulating the body's immune response. The degree of NP internalization and its effect on surface expression of several key markers in immune modulation, CD40, CD86, CD80, HLA-DR and HLA-DQ, were evaluated in primary human dendritic cells (DCs). The results suggest that M12PEG, TL12PEG, TD12PEG, and TMeso12PEG were the most successful NP formulations at modulating a non-specific immune response (adjuvant capacity) in dendritic cells. These studies provide a promising strategy for the design and development of amphiphilic NP adjuvants for potential use as an atherosclerosis vaccine.
KW - Adjuvant
KW - Atherosclerosis
KW - Nanoparticles
KW - Vaccine
UR - http://www.scopus.com/inward/record.url?scp=84940688446&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84940688446&partnerID=8YFLogxK
U2 - 10.1109/NEBEC.2014.6972706
DO - 10.1109/NEBEC.2014.6972706
M3 - Conference contribution
AN - SCOPUS:84940688446
T3 - Proceedings of the IEEE Annual Northeast Bioengineering Conference, NEBEC
BT - Proceedings - 2014 40th Annual Northeast Bioengineering Conference, NEBEC 2014
PB - Institute of Electrical and Electronics Engineers Inc.
T2 - 2014 40th Annual Northeast Bioengineering Conference, NEBEC 2014
Y2 - 25 April 2014 through 27 April 2014
ER -